Myocardial infarction risk and hormone replacement: Differences between products

Corinne de Vries, S Bromley, R Farmer

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: To establish the risk of myocardial infarction (MI) in users of hormone replacement therapy (HRT) compared with non-users and to compare the risk between different HRT regimens.

Methods: A population-based cohort and case-control study, and a case-control study nested within a cohort of HRT users, using the UK General Practice Research Database. Differences between HRT regimen, mode of administration and duration and recency of use were examined whilst adjusting for confounding.

Results: In the cohort and case-control study, 4537 cases of MI were identified in 2.62 million observed women years, cases were age-matched to 27,220 controls. In both studies, current and past HRT use were associated with reduced risk estimates for MI compared with no prior use. MIs were less likely to be fatal amongst women who had used HRT than amongst never users (ORadj 0.58; 95% CI 0.45-0.75). No difference in risk was seen between current and past use, oral and transdermal HRT or between different regimens (p > 0.44). In the nested study, no difference was found in the association with MI risk between different oestrogen-progestogen combinations or between different combinations and tibolone. Unopposed oestrogen use was not associated with a decrease in risk compared with combined HRT.

Conclusions: These results are consistent with previous observational studies in supporting the hypothesis that use of postmenopausal HRT is associated with a decrease in risk of acute myocardial infarction (AMI). Case fatality differed between HRT users and non-users, suggesting a protective effect of HRT. This study does not demonstrate a difference between regimens.

Original languageEnglish
Pages (from-to)343-350
Number of pages8
JournalMaturitas
Volume53
Issue number3
DOIs
Publication statusPublished - 20 Feb 2006

Fingerprint

Hormone Replacement Therapy
Myocardial Infarction
Hormones
Case-Control Studies
tibolone
Estrogens
Estrogen Replacement Therapy
Progestins
General Practice
Observational Studies
Databases

Keywords

  • myocardial infarction
  • risk assessment
  • hormone replacement therapy

Cite this

Myocardial infarction risk and hormone replacement: Differences between products. / de Vries, Corinne; Bromley, S; Farmer, R.

In: Maturitas, Vol. 53, No. 3, 20.02.2006, p. 343-350.

Research output: Contribution to journalArticle

de Vries, Corinne ; Bromley, S ; Farmer, R. / Myocardial infarction risk and hormone replacement: Differences between products. In: Maturitas. 2006 ; Vol. 53, No. 3. pp. 343-350.
@article{2e09e2d812714109bce6516a6c0d8e5f,
title = "Myocardial infarction risk and hormone replacement: Differences between products",
abstract = "Objectives: To establish the risk of myocardial infarction (MI) in users of hormone replacement therapy (HRT) compared with non-users and to compare the risk between different HRT regimens. Methods: A population-based cohort and case-control study, and a case-control study nested within a cohort of HRT users, using the UK General Practice Research Database. Differences between HRT regimen, mode of administration and duration and recency of use were examined whilst adjusting for confounding. Results: In the cohort and case-control study, 4537 cases of MI were identified in 2.62 million observed women years, cases were age-matched to 27,220 controls. In both studies, current and past HRT use were associated with reduced risk estimates for MI compared with no prior use. MIs were less likely to be fatal amongst women who had used HRT than amongst never users (ORadj 0.58; 95{\%} CI 0.45-0.75). No difference in risk was seen between current and past use, oral and transdermal HRT or between different regimens (p > 0.44). In the nested study, no difference was found in the association with MI risk between different oestrogen-progestogen combinations or between different combinations and tibolone. Unopposed oestrogen use was not associated with a decrease in risk compared with combined HRT. Conclusions: These results are consistent with previous observational studies in supporting the hypothesis that use of postmenopausal HRT is associated with a decrease in risk of acute myocardial infarction (AMI). Case fatality differed between HRT users and non-users, suggesting a protective effect of HRT. This study does not demonstrate a difference between regimens.",
keywords = "myocardial infarction, risk assessment, hormone replacement therapy",
author = "{de Vries}, Corinne and S Bromley and R Farmer",
year = "2006",
month = "2",
day = "20",
doi = "10.1016/j.maturitas.2005.06.004",
language = "English",
volume = "53",
pages = "343--350",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Myocardial infarction risk and hormone replacement: Differences between products

AU - de Vries, Corinne

AU - Bromley, S

AU - Farmer, R

PY - 2006/2/20

Y1 - 2006/2/20

N2 - Objectives: To establish the risk of myocardial infarction (MI) in users of hormone replacement therapy (HRT) compared with non-users and to compare the risk between different HRT regimens. Methods: A population-based cohort and case-control study, and a case-control study nested within a cohort of HRT users, using the UK General Practice Research Database. Differences between HRT regimen, mode of administration and duration and recency of use were examined whilst adjusting for confounding. Results: In the cohort and case-control study, 4537 cases of MI were identified in 2.62 million observed women years, cases were age-matched to 27,220 controls. In both studies, current and past HRT use were associated with reduced risk estimates for MI compared with no prior use. MIs were less likely to be fatal amongst women who had used HRT than amongst never users (ORadj 0.58; 95% CI 0.45-0.75). No difference in risk was seen between current and past use, oral and transdermal HRT or between different regimens (p > 0.44). In the nested study, no difference was found in the association with MI risk between different oestrogen-progestogen combinations or between different combinations and tibolone. Unopposed oestrogen use was not associated with a decrease in risk compared with combined HRT. Conclusions: These results are consistent with previous observational studies in supporting the hypothesis that use of postmenopausal HRT is associated with a decrease in risk of acute myocardial infarction (AMI). Case fatality differed between HRT users and non-users, suggesting a protective effect of HRT. This study does not demonstrate a difference between regimens.

AB - Objectives: To establish the risk of myocardial infarction (MI) in users of hormone replacement therapy (HRT) compared with non-users and to compare the risk between different HRT regimens. Methods: A population-based cohort and case-control study, and a case-control study nested within a cohort of HRT users, using the UK General Practice Research Database. Differences between HRT regimen, mode of administration and duration and recency of use were examined whilst adjusting for confounding. Results: In the cohort and case-control study, 4537 cases of MI were identified in 2.62 million observed women years, cases were age-matched to 27,220 controls. In both studies, current and past HRT use were associated with reduced risk estimates for MI compared with no prior use. MIs were less likely to be fatal amongst women who had used HRT than amongst never users (ORadj 0.58; 95% CI 0.45-0.75). No difference in risk was seen between current and past use, oral and transdermal HRT or between different regimens (p > 0.44). In the nested study, no difference was found in the association with MI risk between different oestrogen-progestogen combinations or between different combinations and tibolone. Unopposed oestrogen use was not associated with a decrease in risk compared with combined HRT. Conclusions: These results are consistent with previous observational studies in supporting the hypothesis that use of postmenopausal HRT is associated with a decrease in risk of acute myocardial infarction (AMI). Case fatality differed between HRT users and non-users, suggesting a protective effect of HRT. This study does not demonstrate a difference between regimens.

KW - myocardial infarction

KW - risk assessment

KW - hormone replacement therapy

UR - http://dx.doi.org/10.1016/j.maturitas.2005.06.004

U2 - 10.1016/j.maturitas.2005.06.004

DO - 10.1016/j.maturitas.2005.06.004

M3 - Article

VL - 53

SP - 343

EP - 350

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 3

ER -